信迪利单抗联合化疗治疗非小细胞肺癌的效果及对免疫功能指标的影响

Effect of sintilimab combined with chemotherapy in the treatment of non-small cell lung cancer and its influence on immune function indexes

目的探究信迪利单抗联合白蛋白紫杉醇化疗治疗非小细胞肺癌的效果以及对免疫功能指标和机体不良反应的影响。方法70例非小细胞肺癌患者,根据随机信封法分为对照组与研究组,每组35例。对照组患者采取白蛋白紫杉醇化疗方案,研究组患者采用白蛋白紫杉醇^(+)信迪利单抗化疗。比较两组临床疗效、不良反应发生率以及治疗前后的免疫功能指标。结果研究组总缓解率37.14%、疾病控制率85.71%均高于对照组的11.43%、45.71%,差异均具有统计学意义(P<0.05)。治疗6个周期后,两组患者CD4^(+)、CD4^(+)/CD8^(+)水平高于治疗前,CD8^(+)水平低于治疗前,且研究组患者CD4^(+)(39.56±4.13)%、CD4^(+)/CD8^(+)(1.85±0.46)高于对照组的(35.68±3.79)%、(1.46±0.41),CD8^(+)(20.58±2.46)%低于对照组的(24.16±2.41)%,差异均具有统计学意义(P<0.05)。两组骨髓抑制、肝功能异常、腹泻、输液反应、肺炎、蛋白尿发生率比较,差异均无统计学意义(P>0.05)。研究组甲状腺功能减退症(甲减)发生率31.43%高于对照组的2.86%,差异具有统计学意义(P<0.05)。结论治疗非小细胞肺癌采取信迪利单抗联合白蛋白紫杉醇化疗方案,疗效颇佳,不良反应可控,并有效调节患者血中免疫细胞,改善机体免疫功能。

Objective To investigate the effect of sintilimab combined with chemotherapy in the treatment of non-small cell lung cancer and its influence on immune function indexes.Methods A total of 70 patients with non-small cell lung cancer were divided into a control group and a research group according to random envelope method,with 35 cases in each group.Patients in the control group received chemotherapy combined with albumin paclitaxel,and patients in the research group received chemotherapy combined with albumin paclitaxel and sintilimab.The clinical efficacy,occurrence of adverse reactions,and immune function indexes before and after treatment were compared between the two groups.Results The total remission rate 37.14%and disease control rate 85.71%of the research group were higher than 11.43%and 45.71%of the control group,and the difference was statistically significant(P<0.05).After 6 cycles of treatment,the CD4^(+)and CD4^(+)/CD8^(+)of the two groups were higher than those before treatment,and the CD8^(+)was lower than that before treatment;the CD4^(+)(39.56±4.13)%and CD4^(+)/CD8^(+)(1.85±0.46)of the research group were higher than(35.68±3.79)%and(1.46±0.41)of the control group,and the CD8^(+)(20.58±2.46)%was lower than(24.16±2.41)%of the control group.All the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of bone marrow suppression,abnormal liver function,diarrhea,infusion reaction,pneumonia,and proteinuria between the two groups(P>0.05).The incidence of hypothyroidism in the research group was 31.43%,which was higher than 2.86%in the control group,and the difference was statistically significant(P<0.05).Conclusion Combination of sintilimab and albumin paclitaxel has excellent efficacy on the treatment of non-small cell lung cancer.The adverse reactions are controllable,and the immune cells in the patient’s blood can be effectively regulated to improve the immune function of the body.